Ranger Investment Management L.P. Buys Shares of 2,115,417 ADMA Biologics Inc $ADMA

Ranger Investment Management L.P. purchased a new position in shares of ADMA Biologics Inc (NASDAQ:ADMA) in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 2,115,417 shares of the biotechnology company’s stock, valued at approximately $17,706,000. Ranger Investment Management L.P. owned approximately 0.91% of ADMA Biologics as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also modified their holdings of the business. Royal Bank of Canada boosted its stake in ADMA Biologics by 112.7% in the first quarter. Royal Bank of Canada now owns 95,885 shares of the biotechnology company’s stock valued at $1,903,000 after buying an additional 50,801 shares in the last quarter. Ashton Thomas Private Wealth LLC acquired a new position in ADMA Biologics during the first quarter worth about $217,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in shares of ADMA Biologics by 59.6% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 816,590 shares of the biotechnology company’s stock worth $16,201,000 after acquiring an additional 305,064 shares during the last quarter. Norges Bank bought a new position in shares of ADMA Biologics in the second quarter worth about $549,000. Finally, EverSource Wealth Advisors LLC boosted its stake in shares of ADMA Biologics by 385.8% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,745 shares of the biotechnology company’s stock valued at $50,000 after purchasing an additional 2,180 shares in the last quarter. 75.68% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on the stock. Raymond James Financial started coverage on shares of ADMA Biologics in a research report on Wednesday, June 10th. They set an “outperform” rating and a $21.00 price objective for the company. Weiss Ratings restated a “hold (c)” rating on shares of ADMA Biologics in a research report on Thursday, June 18th. Mizuho decreased their target price on shares of ADMA Biologics from $20.00 to $17.00 and set an “outperform” rating on the stock in a research note on Wednesday, July 15th. Wall Street Zen downgraded shares of ADMA Biologics from a “buy” rating to a “hold” rating in a report on Monday, May 4th. Finally, Zacks Research cut ADMA Biologics from a “hold” rating to a “strong sell” rating in a research note on Tuesday, August 4th. Three research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $18.67.

ADMA Biologics Price Performance

Shares of NASDAQ ADMA opened at $9.84 on Monday. The company has a 50 day simple moving average of $8.96 and a 200 day simple moving average of $10.75. The company has a debt-to-equity ratio of 0.49, a current ratio of 6.97 and a quick ratio of 3.81. ADMA Biologics Inc has a 1 year low of $7.21 and a 1 year high of $20.46. The firm has a market cap of $2.20 billion, a PE ratio of 14.06 and a beta of 0.74.

ADMA Biologics (NASDAQ:ADMA) last posted its earnings results on Wednesday, August 5th. The biotechnology company reported $0.16 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.16. The firm had revenue of $124.39 million for the quarter, compared to analyst estimates of $125.34 million. ADMA Biologics had a net margin of 32.98% and a return on equity of 40.17%. The company’s revenue for the quarter was up 2.0% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.14 EPS. On average, research analysts forecast that ADMA Biologics Inc will post 0.78 EPS for the current year.

ADMA Biologics Company Profile

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.